Slava Akmaev, Ph.D. BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief...
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00...
Global AI in Oncology For Analytical Solutions Market to Transform Cancer Care Accelerating Early Detection, Precision Treatment, and Patient Outcomes....
BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 22, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European pharmaceutical company focused on...
MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant...
MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant...
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice Dr. Raymond Turner Dr. Turner...
Presentation Highlighted Data Supporting Clinical Benefit of GTx-104 Compared to Orally Administered Nimodipine in the Treatment of aneurysmal Subarachnoid Hemorrhage...
PARAMUS, N.J., Sept. 19, 2025 /PRNewswire/ -- NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA)...
MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered...
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...
Updates to McDonald Diagnostic Criteria for MS published NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for...
WEST PALM BEACH, Fla., Sept. 18, 2025 /PRNewswire/ -- On September 12–13, 2025, the Hilton West Palm Beach hosted the Clinical...
Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical...
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apneaNEW...
BUCHAREST, Romania, Sept. 16, 2025 /PRNewswire/ -- Bucharest hosted an important visit this week, as IMPROVATE organized a high-level Israeli medical technology...
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with...
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical...